Clinical trials: IBS-D (Diarrhea-predominant)
Irritable Bowel Syndrome
Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
This study will examine the efficacy, safety and tolerability of oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.
- Trial name
- NCT00189696
- Testing
- YM060
- Where
- 4 sites in Japan
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome
Multi-strain Probiotic in the Management of IBS-D
1. To assess the effect of multistrain probiotics on abdominal pain using a validated symptom severity score in IBS patients. 2.
- Trial name
- NCT03251625
- Testing
- Probiotic Formula Capsule
- Volunteers
- 400 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Irritable Bowel Syndrome
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
A study to verify the superiority of YM060 (ramosetron) to placebo for female patients with diarrhea-predominant irritable bowel syndrome (D-IBS) and to evaluate its safety.
- Trial name
- NCT01274000
- Testing
- YM060
- Where
- 4 sites in Japan
- Volunteers
- 409 people
- Sponsor
- Astellas Pharma Inc
Irritable Bowel Syndrome With Diarrhoea
Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
The purpose of the trial is to define the clinical benefit and possible mediators of the benefit of mesalazine in Irritable Bowel Syndrome (IBS) with diarrhoea.
- Trial name
- MIBS (NCT01316718)
- Testing
- Mesalazine
- Where
- United Kingdom
- Volunteers
- 108 people
- Sponsor
- University of Nottingham